Lab Study of MQX-503 in Treatment of Raynaud's
NCT00253331
·
clinicaltrials.gov ↗
PHASE2,PHASE3
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
Raynaud Disease
Raynaud Disease Secondary to Scleroderma
Raynaud Secondary to Other Autoimmune Disease
Interventions
DRUG:
topical organogel with nitroglycerin
Sponsor
MediQuest Therapeutics